Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 873 - 880 of 12007 results

Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out

April 25, 2024| Blog| Viewpoint

Lawyers Weigh In On How The Federal Ban On Noncompetes Will Affect Massachusetts

April 24, 2024| News

DOJ’s Criminal Division Announces Pilot Program on Voluntary Self-Disclosure for Individuals

April 24, 2024| Blog| Viewpoint

CMS Publishes Final Rules Implementing Part C and Part D Program Changes

April 23, 2024| Blog| Viewpoint

Terminated Sale Of NBA's T-Wolves Looks Like A Power Play

April 23, 2024| News

Empowering Survivors: Spotlight on Mintz’s Pro Bono Champion, Nick Butto

April 23, 2024| News

Misplaced Fears Leave Pregnant Subjects Out Of Drug Trials

April 23, 2024| News

Data Privacy Lawsuits Rise as Lawyers Dust Off Wiretapping Laws

April 23, 2024| News

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases